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Abstract
Background: Both mutational inactivation of the adenomatous polyposis coli (APC) tumor suppressor gene and
activation of the KRAS oncogene are implicated in the pathogenesis of colorectal cancer. Mice harboring a
germline Apc
Min mutation or intestine-specific expression of the KRAS
V12 gene have been developed. Both mouse
strains develop spontaneous intestinal tumors, including adenoma and carcinoma, though at a different age. The
zinc finger transcription factor Krüppel-like factor 5 (KLF5) has previously been shown to promote proliferation of
intestinal epithelial cells and modulate intestinal tumorigenesis. Here we investigated the in vivo effect of Klf5
heterozygosity on the propensity of Apc
Min/KRAS
V12 double transgenic mice to develop intestinal tumors.
Results: At 12 weeks of age, Apc
Min/KRAS
V12 mice had three times as many intestinal tumors as Apc
Min mice. This
increase in tumor number was reduced by 92% in triple transgenic Apc
Min/KRAS
V12/Klf5
+/- mice. The reduction in
tumor number in Apc
Min/KRAS
V12/Klf5
+/- mice was also statistically significant compared to Apc
Min mice alone, with
a 75% decrease. Compared with Apc
Min/KRAS
V12, tumors from both Apc
Min/KRAS
V12/Klf5
+/- and Apc
Min mice were
smaller. In addition, tumors from Apc
Min mice were more distally distributed in the intestine as contrasted by the
more proximal distribution in Apc
Min/KRAS
V12 and Apc
Min/KRAS
V12/Klf5
+/- mice. Klf5 levels in the normal-appearing
intestinal mucosa were higher in both Apc
Min and Apc
Min/KRAS
V12 mice but were attenuated in Apc
Min/KRAS
V12/Klf5
+/-
mice. The levels of b-catenin, cyclin D1 and Ki-67 were also reduced in the normal-appearing intestinal mucosa of
Apc
Min/KRAS
V12/Klf5
+/- mice when compared to Apc
Min/KRAS
V12 mice. Levels of pMek and pErk1/2 were elevated in
the normal-appearing mucosa of Apc
Min/KRAS
V12 mice and modestly reduced in Apc
Min/KRAS
V12/Klf5
+/- mice. Tumor
tissues displayed higher levels of both Klf5 and b-catenin, irrespective of the mouse genotype from which tumors
were derived.
Conclusions: Results of the current study confirm the cumulative effect of Apc loss and oncogenic KRAS activation
on intestinal tumorigenesis. The drastic reduction in tumor number and size due to Klf5 heterozygosity in Apc
Min/
KRAS
V12 mice indicate a critical function of KLF5 in modulating intestinal tumor initiation and progression.
Background
Cancer is the result of deregulated cellular homeostasis
and is typically characterized by increased proliferation
and/or decreased apoptosis [1]. The mammalian intest-
inal epithelium is a continuously renewing system that
is carefully orchestrated throughout life [2]. Several
important signaling pathways are involved in maintain-
ing intestinal epithelial homeostasis and include the
Wnt, Notch, Eph/Ephrin, Hedgehog and bone morpho-
genetic protein (BMP) pathways [2]. It is well estab-
lished that genetic perturbations in proliferation or
differentiation of intestinal epithelial cells can lead to
physiological changes which may aid in the development
of colorectal cancer [3].
Specific mutations have been associated with colorec-
tal carcinogenesis. RAS genes are one of the most fre-
quently mutated oncogenes in human tumors and occur
in approximately 50% of colon cancers [4,5]. There
are three isoforms of the RAS gene, KRAS, HRAS and
NRAS - however, a majority of human tumors possess
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bound protein that is activated by growth factors includ-
ing epidermal growth factor (EGF) and platelet-derived
growth factor (PDGF) [9]. Upon activation, RAS
becomes attached to GTP and elicits a signaling cascade
that induces cell proliferation [10]. KRAS gene is indis-
pensible for normal embryonic survival - targeted
homozygous deletion of the mouse K-ras gene resulted
in embryonic lethality between E12.5 and term [11,12].
In contrast, homozygous deletions in mouse H-r as or
N-ras gene did not result in any significant phenotypic
or viability changes [12-14].
Loss of heterozygosity (LOH) with consequent inacti-
vation of tumor suppressor genes has been causally
implicated in colon cancer formation [8]. One of the
best-characterized tumor suppressor genes in colon can-
cer is the adenomatous polyposis coli (APC) gene. APC
is part of the Wnt signaling pathway that regulates
intestinal epithelial cell proliferation. Inactivation of
APC causes nuclear translocation of normally mem-
brane-bound b-catenin and subsequent activation of the
b-catenin/TCF4 complex with resultant increased prolif-
eration [15-17]. Patients with familial adenomatous
polyposis (FAP) harbor heritable mutations in the APC
gene and spontaneously develop adenomatous polyps
throughout their intestinal tracts at an early age [18,19].
The APC gene is also inactivated in greater than 80% of
sporadic colorectal cancer [20]. An autosomal dominant
mouse model of multiple intestinal neoplasia (Min) was
developed in C57BL/6 mice upon ethylnitrosourea treat-
ment [21]. This mouse strain carries a germline muta-
tion in the mouse Apc gene, resulting in truncation of
the protein at amino acid position 850 [22]. As a result,
Apc
Min mice exhibit a phenotype similar to that of FAP
patients [22].
Krüppel-like factors (KLFs) are zinc finger-containing,
Sp1-like transcription factors that are involved in diverse
physiological processes including proliferation, differen-
tiation and embryonic development [23,24]. In the intes-
tine, Krüppel-like factor 5 (KLF5) is predominantly
expressed in the proliferating crypt epithelial cells
[25,26]. KLF5 is important for embryonic development
since homozygous deletion of Klf5 in mice is embryonic
lethal [27]. We previously demonstrated that KLF5 has a
pro-proliferative effect in cultured cells and does so by
activating cell cycle regulatory proteins such as cyclin
D1, cyclin B1 and Cdc2 [28,29]. In addition, KLF5 has
been shown to be an important mediator of the HRAS
and KRAS oncogenic pathways [28,30] as well as the
Wnt pathway [31]. Adenomas and carcinomas in mice
that express oncogenic KRAS
V12 from the intestine-spe-
cific villin promoter have increased KLF5 expression
[30]. In addition, we recently showed that adenoma for-
mation in Apc
Min mice was significantly abrogated when
Apc
Min mice were bred to mice heterozygous for Klf5
[32]. We further showed that KLF5 interacts with b-
catenin and facilitates the nuclear localization and tran-
scriptional activity of b-catenin [32]. These studies sug-
gest that KLF5 is an essential mediator of intestinal
tumorigenesis in the context of Apc
Min mutation.
Since KLF5 has been shown to mediate the function
of both APC and RAS, and mutations in APC and KRAS
are common events in colorectal cancer, we examined
the role of KLF5 in mediating intestinal tumor forma-
tion in mice compound for Apc
Min and intestine-specific
KRAS
V12 mutations in the current study.
Results
Klf5 heterozygosity reduces intestinal adenoma formation
in Apc
Min/KRAS
V12 mice
To determine the effect of Klf5 heterozygosity on intest-
inal adenoma formation in mice that harbor both Apc-
Min and KRAS
V12 mutations, we crossed mice that were
heterozygous for the Apc
Min and Klf5 genes with those
that were heterozygous for the KRAS
V12 gene directed
by the intestine-specific villin promoter [33]. Intestines
from the resulting progeny were assessed for tumor
number and size at 12 weeks of age. Tumors were
observed in mice from three genotypes of the resulting
progeny (Apc
Min, Apc
Min/KRAS
V12 and Apc
Min/KRAS
V12/
Klf5
+/-)b u tn o ti nApc
Min/Klf5
+/- or KRAS
V12mice. The
mice with the compound Apc
Min/KRAS
V12 genotype had
a greater propensity for developing tumors in the small
intestine than the Apc
Min mice (Fig. 1A). The latter had
an average of 71 small intestinal tumors per mouse
while Apc
Min/KRAS
V12 mice had an average of 226
tumors. The deletion of one of the Klf5 alleles in Apc-
Min/KRAS
V12 mice reduced the average tumor number
to 19 per mouse - a 92% reduction (Fig. 1A). In the
colon, the number of tumors per mouse was much
fewer compared to the small intestine, with no signifi-
cant differences in numbers of tumors between the
three genotypes (Fig. 1B). Fig. 1C shows the combined
tumor burden in both the small intestines and colons of
the three different strains of mice.
Haploinsufficiency of Klf5 decreases intestinal tumor size
in Apc
Min/KRAS
V12 mice
In addition to tumor number, we measured the tumor
size from the mice described above. The majority of the
tumors, irrespective of genotype, were less than 1 mm
in size (Fig. 2A). However, the percentage of tumors
that were smaller than 1 mm in Apc
Min/KRAS
V12 mice
(49% overall) was lower than either Apc
Min (69% overall)
or Apc
Min/KRAS
V12/Klf5
+/- (62% overall) mice. In con-
trast, Apc
Min/KRAS
V12 mice had a higher percentage of
tumors that were 1-2 mm in size (39%) when compared
to Apc
Min/KRAS
V12/Klf5
+/- mice (33%) or Apc
Min mice
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Min/KRAS
V12 mice also
displayed a greater number of tumors that were 2-3 mm
or greater than 3 mm when compared to the other two
genotypes. These differences in tumor size showed a sta-
tistically significant trend when analyzed by the Chi-
square test.
Change in intestinal tumor localization in mice that
possess the KRAS
V12 genotype in addition to the Apc
Min
genotype
An interesting observation when comparing intestinal
tumors among the different genotypes concerned the
localization of the tumors. We observed that a larger
percentage of tumors in Apc
Min mice were localized in
the distal small intestine, predominantly in the ileum
(57%) and the jejunum (36%) (Fig. 2B). In contrast, both
Apc
Min/KRAS
V12 and Apc
Min/KRAS
V12/Klf5
+/- mice con-
tained a higher percentage of intestinal tumors in the
proximal small intestine, duodenum (44% and 64%,
respectively) when compared to the Apc
Min mice (7%)
(Fig. 2B). These differences were found to be statistically
significant using the Chi-square test.
We then determined the level of KRAS transcripts in
intestinal tissues from mice with the different genotypes
using quantitative PCR. Both Apc
Min/KRAS
V12 mice and
Apc
Min/KRAS
V12/Klf5
+/- mice contained high levels of
exogenous (human) KRAS mRNA in the intestine while
wild type and Apc
Min mice had only background expres-
sion (Fig. 3A). Since uneven KRAS expression could
potentially contribute to the altered regional localization
in the intestines of mice harboring KRAS
V12, we mea-
sured both endogenous (mouse) and exogenous
Figure 1 The effect of Klf5 heterozygosity on intestinal tumor burden in Apc
Min/KRAS
V12 mutant mice at 12 weeks of age.T u m o r
burden is plotted as the number of tumors per mouse on the Y-axis. Tumor number from each individual mouse is shown as an open symbol,
while the averages of the tumor numbers are represented as black bars. (A) Tumor burden in the small intestine; N = 8 for each genotype and
**, P < 0.01. (B) Tumor burden in the colon; N = 8 for each genotype. (C) Overall tumor burden including both the small intestine and colon;
N = 8 for each genotype and **, P < 0.01.
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Page 3 of 14Figure 2 Assessment of intestinal tumor size and distribution in mutant mice. Percentages of intestinal tumors are displayed in bar graphs,
with black bars representing Apc
Min mice, white bars representing Apc
Min/KRAS
V12 mice and gray bars indicating Apc
Min/KRAS
V12/Klf5
+/- mice. (A)
Graph displaying tumor sizes in the small intestine. The tumors are sized based on 4 categories, <1 mm, 1-2 mm, 2-3 mm and >3 mm. Average
percentages of tumors are represented on the Y-axis and tumor size categories on the X-axis; N = 8 and groups show a significant trend based
on a one-way ANOVA test with P < 0.05. (B) Graph displaying tumor location in the small intestine. Tumor locations in the small intestine are
divided into duodenum, jejunum and ileum. The graph is plotted with average percentage of tumors on the Y-axis and tumor locations on the
X-axis; N = 8 and groups show a significant trend based on a one-way ANOVA test with P < 0.05.
Figure 3 Quantification of exogenous and endogenous KRAS transcript levels in the small intestine of mutant mice. KRAS transcript
levels were measured using quantitative PCR analysis. RNA was extracted from paraffin-embedded intestinal tissue samples. Endogenous
(mouse) and exogenous (human) KRAS expression was measured and compared against b-actin. Fold changes were calculated for KRAS levels
against b-actin levels using the 2
-ΔΔCt method of relative quantification [60]. (A) Relative fold changes in exogenous (human) KRAS transcript
levels in mutant mice compared to the wild type (WT) mice (designated as 1). (B) Relative fold changes in mouse Kras and human KRAS
transcript levels in different regions (D = duodenum; J = jejunum; I = ileum) of the mutant mouse intestines.
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the intestine. We found that levels of exogenous KRAS
transcripts were highly elevated in all three segments of
the intestine of Apc
Min/KRAS
V12 mice, with no signifi-
cant regional differences (Fig. 3B). Similarly, no regional
differences in the levels of endogenous Kras were found
in the intestines of either Apc
Min or Apc
Min/KRAS
V12
mice (Fig. 3B).
Klf5 heterozygosity results in reduced levels of pro-
proliferative proteins in the intestines of Apc
Min and
Apc
Min/KRAS
V12 mice
We previously showed that KLF5 is pro-proliferative in
the normal intestinal epithelial cells [30,34] and is
increased in tumors from mice that contain the Apc
Min
allele [32] or the KRAS
V12 allele [30]. Here we observed
increased levels of Klf5 protein in the normal-appearing
small intestinal tissues of both Apc
Min and Apc
Min/
KRAS
V12 mice when compared to that of wild type mice
( F i g .4 A - C ) .T h ei n t r o d u c t i o no fam u t a n tKlf5 allele
into Apc
Min/KRAS
V12 mice resulted in a reduction in
Klf5 (Fig. 4D) to a level that was more similar to the
wild type intestine (Fig. 4A). Similarly, the levels of b-
catenin were increased in the normal-appearing intest-
inal tissues of Apc
Min and Apc
Min/KRAS
V12 mice when
compared to wild type mice (Fig. 4E-G). Again, this
increase in b-catenin was attenuated in the Apc
Min/
KRAS
V12/Klf5
+/- mice (Fig. 4H). Moreover, an increase
Figure 4 Immunohistochemical analyses of Klf5 and b-catenin in the normal-appearing small intestines of wild type and mutant mice.
The panels are representative sections of normal-appearing small intestinal tissues stained with Klf5 (A-D) or b-catenin antibodies (E-H). Formalin-
fixed, paraffin-embedded tissue sections (5 μm in size) were deparaffinized and antigen-retrieved using Citrate buffer (pH 6.0). Sections were
stained with appropriate primary and secondary antibodies and developed using DAB chromogen. The resulting brown color is representative of
protein expression. The sections were also counter stained with hematoxylin, which stains the nuclei blue. Panels A & E represent Klf5 and b-
catenin staining, respectively, in wild type (WT) normal intestinal tissues. Panels B & F show staining in Apc
Min tissues, while panels C & G and
panels D & H show representative staining in Apc
Min/KRAS
V12 and Apc
Min/KRAS
V12/Klf5
+/- tissues, respectively.
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epithelial cells of Apc
Min and Apc
Min/KRAS
V12 mice
compared to wild type mice (Fig. 5A-C). Similar to total
b-catenin, the number of crypt epithelial cells containing
nuclear b-catenin was reduced in Apc
Min/KRAS
V12/Klf5
+/-
mice relative to Apc
Min and Apc
Min/KRAS
V12 mice
(Fig. 5D). These results indicate that Klf5 modulates both
steady-state b-catenin levels and cellular localization of
b-catenin in intestinal epithelial cells secondary to the
Apc
Min mutation.
We then performed immunohistochemical analyses
on cyclin D1, a shared target between KLF5 and b-
catenin [32]. Similar to the expression patterns of Klf5
and b-catenin, there was an increase in cyclin D1
levels in the intestine of both Apc
Min and Apc
Min/
KRAS
V12 mice when compared to that of wild type
mice (Fig. 6A-C). Cyclin D1 staining in the normal-
appearing intestinal epithelium in Apc
Min/KRAS
V12/
Klf5
+/- mice was reduced when compared to Apc
Min
and Apc
Min/KRAS
V12 mice, except for a small focus of
adenomatous tissue where cyclin D1 remained high
(Fig. 6D). We also quantified cyclin D1 levels by quan-
titative image analysis (Fig. 6E) and Western blot ana-
lysis (Fig. 6F). As seen, both measurements confirmed
the trend of cyclin D1 levels in the intestine from mice
of the four genotypes as revealed by immunohisto-
chemical staining. Similar trends in the levels of Klf5
and b-catenin were also documented by Western blot
analysis (Fig. 6F). Lastly, levels of the proliferation
marker, Ki67, in the normal-appearing intestinal tis-
sues of the four strains of mice closely paralleled the
levels of Klf5, b-catenin and cyclin D1, by immunohis-
tochemical staining (Fig. 7A-D) and image quantifica-
tion (Fig. 7E).
Figure 5 Nuclear localization of b-catenin in the normal-appearing small intestines of wild type and mutant mice. Panels are magnified
immunohistochemical images of representative small intestinal crypts stained with b-catenin antibodies. Red arrowheads in all the panels
indicate nuclear b-catenin staining.
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activated in the intestinal mucosa of Apc
Min/KRAS
V12 mice
We previously established that MAPK pathway, as
reflected by ERK phosphorylation, was an important
intermediate in oncogenic KRAS-mediated induction of
KLF5 [28,30]. Hence, we immunostained samples of
small intestinal tissues for phospho-MEK and phospho-
ERK proteins. We found that staining intensities for
pMek were increased in normal-appearing small intest-
inal epithelial cells from both Apc
Min and Apc
Min/
KRAS
V12 mice when compared to wild type mice (Fig.
8A-C). A moderate reduction in pMek staining was
noted in the intestine of Apc
Min/KRAS
V12/Klf5
+/- mice
compared to that of Apc
Min/KRAS
V12 mice (Fig. 8C
&8D). A similar pattern was also observed when pErk1/
2 staining was performed (Fig. 8E-H). These results indi-
cate that the MAPK pathway is activated in the intestine
of Apc
Min/KRAS
V12 mice and that Klf5 heterozygosity
modestly reduces this activation.
Intestinal tumors have increased Klf5 and b-catenin
expression irrespective of genotype
We also stained intestinal tumors derived from Apc
Min,
Apc
Min/KRAS
V12 and Apc
Min/KRAS
V12/Klf5
+/- mice for
Klf5 and b-catenin. As seen in Fig. 9, the levels of both
Klf5 and b-catenin were elevated in the adenomatous
tissues of all three strains compared to the normal-
appearing intestinal tissues. These results indicate that
despite the differences in expression among proliferative
markers in the normal intestinal epithelia of the mutant
Figure 6 Immunohistochemical and Western blot analyses of cyclin D1 in the normal-appearing small intestinal tissues of wild type
and mutant mice. (A-D) Immunohistochemical staining of cyclin D1 in the normal-appearing small intestines of wild type (WT) and mutant
mice. A small focus of adenomatous tissue is demarcated by the red broken lines in panel D. (E) Quantification of cyclin D1 staining intensities
in all fours sections using the Metamorph image analysis software. N = 10; **, P < 0.01. (F) Western blot analyses of Klf5, b-catenin, and cyclin D1
in the small intestines of wild type and mutant mice. Actin serves as a loading control.
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tumor tissues irrespective of genotype.
Discussion
Colorectal cancer is the result of cumulative mutations
in genes involved in regulating proliferation or apopto-
sis. APC is an integral part of the Wnt signaling path-
way that regulates intestinal epithelial homeostasis [35].
Inactivation of APC is synonymous with Wnt activation
and has been shown to be causal to colorectal carcino-
genesis [35]. Also, among the frequently mutated genes
in colorectal cancer is KRAS, specifically in codons 12,
13 and 61 [36-39]. It was shown that mutations in APC
and KRAS occur in approximately 80% and 50%, respec-
tively, of sporadic colorectal cancer [4,5,20]. Recent stu-
dies aimed at comprehensive sequencing of genes
mutated in colorectal cancer confirmed that APC and
KRAS mutations are among the most common muta-
tions found in colorectal cancer [40,41].
R e s u l t so fo u rs t u d yc o n f i r m e dt h ec o o p e r a t i v ee f f e c t
of activated Wnt and RAS signaling in mice. At 12
weeks of age, compound heterozygous Apc
Min/KRAS
V12
mice developed more and larger small intestinal tumors
than Apc
Min mice alone (Figs. 1A and 2A). In compari-
s o n ,a tt h es a m ea g e ,KRAS
V12 mice did not have any
tumor, consistent with the previous finding that these
Figure 7 Immunohistochemical analyses of Ki67 in the normal-appearing small intestinal tissues of wild type and mutant mice. (A-D)
Immunohistochemical staining of Ki67 in the normal-appearing small intestines of wild type (WT) and mutant mice. (E) Quantification of Ki67
cyclin D1 staining intensities in all fours sections using the Metamorph image analysis software. N = 10; **, P < 0.01.
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This cooperative nature between Apc and KRAS muta-
tions in leading to increased tumor formation is similar
to that observed in two previous studies, one involving
Apc
+/1638/KRAS
V12 double transgenic mice [42] and the
other Apc
Min/K-ras
D12 double transgenic mice [43].
While there was a trend for a higher number of colo-
nic tumors in the Apc
Min/KRAS
V12 as compared to Apc-
Min mice alone in our study (Fig. 1B), the difference did
not reach statistical significance, due to the relatively
small number of tumors in this region. The propensity
for the Apc
Min, Apc
+/1638, KRAS
V12, Apc
+/1638/KRAS
V12
mice to develop tumors in the small intestine rather
than the colon has been reported [21,33,42]. It is of
interest to note that there is a difference in regional dis-
tribution of small bowel tumors between Apc
Min and
Apc
Min/KRAS
V12 mice - tumors in the former mice were
more distally distributed while those in the latter were
more proximally distributed (Fig. 2B). This difference in
tumor distribution does not appear to be due to regional
variations in expression of the KRAS
V12 transgene from
the villin promoter (Fig. 3B). The effect of KRAS
V12
allele introduction on the shift in tumor distribution
more proximally is therefore not clear at this time. A
similar trend toward distribution of small bowel tumors
in the Apc
Min mice has been reported [44].
We recently reported the critical role for Klf5 in
tumor initiation in Apc
Min mice [32]. Klf5
Figure 8 Phosphorylation of MEK and ERK in the normal-appearing small intestinal tissues of wild type and mutant mice.
Immunohistochemical analyses were performed with phospho-Mek (pMek; A-D) and Phospho-Erk1/2 (pErk; E-H) antibodies. WT is wild type.
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Min mice resulted in a signifi-
cant decrease in tumor number and size [32]. Results of
the current study demonstrate a similar effect on tumor
formation at 12 weeks of age in Apc
Min/KRAS
V12 mice
that were heterozygous for the Klf5 alleles, with the
intestinal tumor burden reduced by more than 90% in
the triple Apc
Min/KRAS
V12/Klf5
+/- transgenic mice when
compared to the double Apc
Min/KRAS
V12 transgenic
mice (Fig. 1). In addition, the tumors in the Apc
Min/
KRAS
V12/Klf5
+/- mice, when formed, were smaller than
those from the Apc
Min/KRAS
V12 mice (Fig. 2A). Indeed,
Apc
Min/KRAS
V12 mice had to be euthanized by 12 weeks
of age, due to the presence of rectal prolapse from the
large tumor burden. In contrast, the majority of Apc
Min/
KRAS
V12/Klf5
+/- mice survived up to a year without
displaying overt morbidity. Taken into consideration
that expression of the KRAS
V12 transgene in the small
intestine of Apc
Min/KRAS
V12/Klf5
+/- mice remains robust
(Fig. 3A), our study suggests that haploinsufficiency of
Klf5 attenuates the cumulative effect of Apc inactivation
and oncogenic KRAS activation.
Our results show that a combined effect of Apc
Min
and KRAS
V12 mutations is a significant increase in the
levels of b-catenin, cyclin D1 and Ki67, in the normal-
appearing intestinal tissues in the Apc
Min/KRAS
V12 mice
as compared to wild type mice (Figs. 4, 5, 6, 7). This
increase is similar to that seen in the intestine from the
Apc
Min mice (Figs. 4, 5, 6, 7). Haploinsufficiency of Klf5
attenuated the increase in the levels of these three pro-
teins in the normal-appearing intestine of Apc
Min/
Figure 9 Immunostaining of Klf5 and b-catenin in intestinal adenomas derived from mutant mice. Adenomatous tissues from Apc
Min,
Apc
Min/KRAS
V12 and Apc
Min/KRAS
V12/Klf5
+/- mice were formalin-fixed, paraffin-embedded and cut into 5 μm sections. Slides were then stained
with Klf5 and b-catenin antibodies after deparaffinization and antigen-retrieval. Protein expression was determined upon secondary antibody
treatment and color development using DAB chromogen (brown stain). Nuclei were then counterstained blue using hematoxylin. Panels A & D
represent Klf5 and b-catenin staining in Apc
Min tumor tissues. Panels B & E represent comparative staining in Apc
Min/KRAS
V12 tumor tissues, while
panels C & F represent staining in Apc
Min/KRAS
V12/Klf5
+/- tumor tissues.
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V12 mice to levels that resembled the wild type
intestine (Figs. 4, 5, 6, 7). These results indicate that
the increase in b-catenin and cyclin D1 levels in the
intestine of mutant mice is primarily a consequence of
Apc
Min mutation, rather than KRAS
V12 over-expression
and that the tumor suppressive effect of Klf5 haploin-
sufficiency in Apc
Min/KRAS
V12 mice is due primarily to
the ability of Klf5 to modulate Apc
Min signaling. These
notions are supported by the observation that
increased nuclear localization of b-catenin is observed
in the normal-appearing intestinal crypt epithelial cells
of both Apc
Min and Apc
Min/KRAS
V12 mice but was sig-
nificantly reduced in the crypt cells of Apc
Min/
KRAS
V12/Klf5
+/- mice (Fig. 5). The se findings are con-
sistent with our previous observation that Klf5 both
stabilizes b-catenin and facilitates nuclear import of b-
catenin [32]. However, it should be noted that a recent
report showed that activated KRAS also facilitates
nuclear translocation of b-catenin following loss of
Apc in zebrafish [45]. Moreover, we have shown that
KRAS
V12 increases KLF5 expression in vitro and in
vivo [30]. Combining the results of these studies, it is
highly plausible that KLF5 is a common mediator for
the increased b-catenin activity due to both APC loss
and KRAS activation.
MEK and ERK phosphorylation are hallmarks of acti-
vation of the RAS signaling pathway which stimulates
cell proliferation [46]. We previously reported that
MEK/ERK phosphorylation is essential for mediating
oncogenic RAS-induced KLF5 expression in vitro
[28,30]. Previous studies have documented enhanced
MEK/ERK protein phosphorylation in mice containing
both oncogenic KRAS mutations and Apc inactivation
[47,48]. Results of the current study showed a similar
increase in MEK/ERK phosphorylation in the normal-
appearing intestines of mice with Apc
Min mutation that
is further enhanced upon oncogenic KRAS activation
(Fig. 8). Upon heterozygous loss of Klf5 in Apc
Min/
KRAS
V12 mice, MEK/ERK phosphorylation levels are
only modestly reduced. These results suggest that RAS
activation of MEK/ERK phosphorylation is upstream of
KLF5 induction, although KLF5 could potentially regu-
late MEK/ERK phosphorylation through a feedback
mechanism, as previously proposed [49].
Our study adds to a growing list of literature demon-
strating the combined effect of Apc and KRAS mutation
on intestinal tumorigenesis in mice [42,43,50,51]. In the
setting of Apc mutation, inhibition of intestinal tumor
formation has been documented secondary to deletion
of several genes crucial for tumorigenesis [32,52-56].
However, ours is the first in which to show a critical
role of Klf5 in mediating the tumorigenic effect of com-
bined Apc and KRAS mutations, a commonly encoun-
tered scenario in colorectal cancer in humans. This
suggests that therapies targeted to KLF5 may have
potential therapeutic benefit to patients with colorectal
cancer. Indeed, a recent screen for small molecule inhi-
bitors of KLF5 expression has yielded several potent
compounds that inhibit proliferation of colorectal cancer
cells [57]. Further investigation may prove KLF5 an
attractive target for intervention in the prevention or
treatment of colorectal cancer.
Conclusions
Loss of tumor suppressor genes and activation of onco-
genes are hallmarks of cancers. In the case of colorectal
cancer, loss of APC and activation of KRAS are com-
mon. Here, we present a robust mouse model of intest-
inal tumorigenesis with the generation of Apc
Min/
KRAS
V12 mice. These mice display an increased propen-
sity for developing intestinal tumors at an early age
compared to Apc
Min mice. Moreover, we were able to
significantly reduce tumor burden and size in the com-
pound Apc
Min/KRAS
V12 mice by reducing expression of
Klf5 with genetic means. Apc
Min/KRAS
V12/Klf5
+/- mice
display reduced levels of Klf5 protein as well as b-cate-
nin, cyclin D1 and Ki67, all known markers of prolifera-
tion and transformation. We conclude that Klf5 is a
crucial mediator of initiation and progression of intest-
inal tumors resulted from Apc
Min and KRAS
V12
mutations.
Methods
Reagents
Antibodies used in the experiments were previously
described [30,32]. Antibodies against KLF5 were gener-
ated against a synthetic KLF5 peptide in rabbits (Strate-
gic Diagnostics, Newark, DE). Anti-KLF5 antibody was
used at a dilution of 1:15,000 for immunohistochemistry
and at 1:4,000 for Western blot analysis. Mouse mono-
clonal antibody against total b-catenin was purchased
from Invitrogen (Carlsbad, CA) and used at a dilution of
1:1,000 for Western blot analyses. For immunohisto-
chemical analysis, total b-catenin antibodies purchased
from BD Biosciences (San Jose, CA) were used at 1:250
dilutions. Rabbit monoclonal cyclin D1 antibodies were
purchased from Biocare Medical (Concord, CA) and
used at 1:200 dilutions in immunohistochemical analyses
and 1:2,500 dilutions for Western blot analysis. Anti-
Ki67 antibodies were purchased from Novocastra (Leica
Microsystems, Bannockburn, IL) and used at 1:500 dilu-
tions. Anti-Phospho-MEK1 and anti-Phospho-ERK1/2
antibodies, used at 1:100 dilutions, were purchased from
Cell Signaling Technology (Danvers, MA).
Mice
All studies involving mice have been approved by the
Emory University Institutional Animal Care and Use
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KRAS
V12 expressed from a mouse villin promoter were
previously generated [33]. Mice double heterozygous for
Apc
Min and Klf5
+/- alleles were generated as previously
described [32]. Founder C57BL/6J mice that were hetero-
zygous Apc
Min alleles (males) were mated with those that
were heterozygous for Klf5
+/- alleles (females). The
resulting progeny generated double heterozygous Apc-
Min/Klf5
+/- mice. These mice were then mated with the
KRAS
V12 mice to generate the triple transgenic mice used
in this study. Littermates of the crosses consisted of mice
wild type for all alleles, mice that were heterozygous for
only one of the three alleles, mice with two heterozygous
alleles and mice with all three heterozygous alleles. Out
of this progeny wild type, Apc
Min, Apc
Min/KRAS
V12 and
Apc
Min/KRAS
V12/Klf5
+/- mice were used for the study.
Genotype analyses
Genotype analyses were performed as previously
described [58]. Tail-tips from newly weaned mice were
collected and processed using the Red Extract-N-Amp
kit as per protocol (Sigma Aldrich, St. Louis, MO).
Allele-specific PCR analyses were performed using 2 μl
of mouse DNA and appropriate primers for genotypic
analyses. Primers to identify KLF5, Apc
Min mutation,
and villin-KRAS have been previously described
[33,58,59].
Tumor assessment
Mice were sacrificed at 12 weeks of age by CO2 asphyx-
iation, as per IACUC guidelines. The mice were dis-
sected and the small intestine and colon removed. The
intestinal tissues were cleaned with phosphate-buffered
saline (PBS) and cut open. Using a dissecting micro-
scope, the intestinal tissues were examined in a blinded
fashion, for the presence and size measurements of
tumors. The adenomas found were counted and mea-
sured according to <1 mm, 1-2 mm, 2-3 mm and >3
mm size groups.
RNA purification and quantitative PCR
RNA was extracted from formalin-fixed paraffin-
embedded tissue samples using the RT
2 FFPE RNA
extraction kit (SA Biosciences, Frederick, MD). Sixty μm
tissue sections were cut from paraffin sample blocks and
digested with Proteinase K for 30 minutes. Samples were
then boiled and centrifuged to remove paraffin. RNA was
extracted from the liquid samples using Trizol LS reagent
(Invitrogen, Carlsbad, CA) and subsequently purified
using a spin column. RNA was quantified and used
(100 ng/sample) in quantitative PCR. Specific primers
against mouse KRas, human KRAS and mouse b-actin
were purchased from SA Biosciences (Frederick, MD)
and Qiagen (Valencia, CA) respectively. Quantitative
PCR was performed using the Power SYBR Green RNA-
to-CT 1-Step kit (Invitrogen, Carlsbad, CA) as per protocol.
Observed CT levels were then used to calculate fold change
using the 2
-ΔΔCt method of relative quantification [60].
Immunohistochemistry
Immunohistochemical analysis was performed as pre-
viously described [30]. Intestinal tissues dissected from
mice were fixed overnight with 10% formalin buffer
(Thermo Fisher Scientific, Fair Lawn, NJ). The tissues
were then paraffinized using a tissue paraffinizer (Shandon
Excelsior and Histocenter, Thermo Scientific, NJ). The
paraffinized tissues were embedded onto paraffin blocks
and cut into 5 μm sections using a microtome (Microm,
Thermo Scientific, NJ). The sections were then dried onto
charged slides and used for staining. The slides containing
paraffin-embedded tissue sections were deparaffinized by
baking in a 60°C oven for 1 hr and subsequent incubation
in a xylene bath. Sections were incubated in a 5% hydro-
gen peroxide bath to block endogenous tissue peroxidases.
The sections were then hydrated by incubation in a
decreasing alcohol bath series (100%, 95%, 70%) followed
by antigen retrieval in citrate buffer solution (10 mM
Sodium citrate, 0.05% Tween-20, pH 6.0) at 125°C for 10
min using a decloaking chamber (Biocare Medical, CA).
Tissue sections were then incubated with blocking buffer
containing avidin (2% milk, 0.05% Tween-20, 5% normal
serum) for 30 min at 37°C. Subsequently, antibodies, with
Biotin, were added to the blocking buffer at appropriate
concentrations and incubated with tissue sections for 1 hr
at 37°C. Sections were washed and incubated with second-
ary antibodies at the appropriate concentration for 30 min
at 37°C. Vectorstain ABC solution (Vector Labs, Burlin-
game, CA) and Betazoid DAB (Biocare Medical, CA) were
used to reveal staining in tissues. The sections were then
incubated in Gill’s Hematoxylin (Vector Labs, CA), dehy-
drated and cover-slipped for observation. Slides were
observed under a Zeiss Axioskop (Carl Zeiss MicroIma-
ging, Thornwood, NY) and representative pictures taken.
Quantification of immunohistochemical staining intensity
Staining intensities for immunohistochemical analyses
were quantifies using Metamorph image analysis soft-
ware (Version 7.1.1) (Molecular Devices, Downington,
PA). Individual images were specifically quantified as
previously described [30].
Western blot analyses
Western blot analyses were performed as previously
described [28]. Proteins were extracted from 20 μm par-
affin embedded tissue sections using a previously estab-
lished protocol [61]. Tissue sections were deparaffinized
using xylene with the addition of 7.5% methanol. Sam-
ples were then centrifuged and the pellet dried in a
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pended in 20 mM Tris-HCl (pH 7.5) containing 2% SDS
and the suspension heated in a 100°C heat block for 20
min. Subsequently, the samples were incubated in a 60°
C oven for 2 hr. Protein content was measured and
equal amounts of samples were loaded onto Bis-Tris
gels (Invitrogen, CA). Proteins were transferred to nitro-
cellulose membranes (BioRad, Hercules, CA) and probed
with appropriate primary antibodies. Blots were then
washed and secondary antibodies applied at appropriate
concentrations. Protein bands were then visualized on
film upon chemiluminescent detection.
Statistical analysis
A one-way ANOVA was used to compare mean num-
bers of tumors between Apc
Min, Apc
Min/KRAS
V12,a n d
Apc
Min/KRAS
V12/Klf5
+/- mice given independence of
samples, equality of variances as tested by Levene’st e s t ,
and a Gaussian distribution of the data. Multiple pair
wise comparisons were made among groups using
Tukey’s test. Tumors were categorized based on size
into 4 ordinal categories (<1 mm, 1-2 mm, 2-3 mm, and
greater than 3 mm) using previously published measure-
ment protocols [30]. Proportions of tumors among size
categories were compared between Apc
Min, Apc
Min/
KRAS
V12, and Apc
Min/KRAS
V12/Klf5
+/- mice using a Chi-
square test for homogeneity. P < 0.05 was considered
indicative of statistical significance. Similar methods
were used to ascertain statistical significance in relation
to tumor location. The statistical software package SAS
9.2 was used for statistical analysis.
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